InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Lackner Mark. Director active across 1 company, notably Zentalis Pharmaceuticals, Inc.. Cumulatively, 4 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €13k. History available since 2 January 2024. The latest transaction was disclosed on 3 February 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
4 of 4 declarations